288 related articles for article (PubMed ID: 28817561)
1. Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach.
Pienaar E; Sarathy J; Prideaux B; Dietzold J; Dartois V; Kirschner DE; Linderman JJ
PLoS Comput Biol; 2017 Aug; 13(8):e1005650. PubMed ID: 28817561
[TBL] [Abstract][Full Text] [Related]
2. Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.
Willby M; Sikes RD; Malik S; Metchock B; Posey JE
Antimicrob Agents Chemother; 2015 Sep; 59(9):5427-34. PubMed ID: 26100699
[TBL] [Abstract][Full Text] [Related]
3. Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India.
Mamatha HG; Shanthi V
J Glob Antimicrob Resist; 2018 Mar; 12():5-10. PubMed ID: 28887289
[TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations.
Sarathy J; Blanc L; Alvarez-Cabrera N; O'Brien P; Dias-Freedman I; Mina M; Zimmerman M; Kaya F; Ho Liang HP; Prideaux B; Dietzold J; Salgame P; Savic RM; Linderman J; Kirschner D; Pienaar E; Dartois V
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30803965
[TBL] [Abstract][Full Text] [Related]
5. Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach.
Pranger AD; Alffenaar JW; Aarnoutse RE
Curr Pharm Des; 2011; 17(27):2900-30. PubMed ID: 21834759
[TBL] [Abstract][Full Text] [Related]
6. Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas.
Pienaar E; Linderman JJ; Kirschner DE
PLoS One; 2018; 13(5):e0196322. PubMed ID: 29746491
[TBL] [Abstract][Full Text] [Related]
7. A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment.
Pienaar E; Cilfone NA; Lin PL; Dartois V; Mattila JT; Butler JR; Flynn JL; Kirschner DE; Linderman JJ
J Theor Biol; 2015 Feb; 367():166-179. PubMed ID: 25497475
[TBL] [Abstract][Full Text] [Related]
8. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo.
Veziris N; Truffot-Pernot C; Aubry A; Jarlier V; Lounis N
Antimicrob Agents Chemother; 2003 Oct; 47(10):3117-22. PubMed ID: 14506018
[TBL] [Abstract][Full Text] [Related]
9. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
Almeida D; Nuermberger E; Tyagi S; Bishai WR; Grosset J
Antimicrob Agents Chemother; 2007 Dec; 51(12):4261-6. PubMed ID: 17938193
[TBL] [Abstract][Full Text] [Related]
10. Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB.
Van Deun A; Decroo T; Kuaban C; Noeske J; Piubello A; Aung KJM; Rieder HL
Int J Tuberc Lung Dis; 2019 Sep; 23(9):965-971. PubMed ID: 31615602
[No Abstract] [Full Text] [Related]
11. Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis.
Sterling TR
Int J Tuberc Lung Dis; 2016 Dec; 20(12):42-47. PubMed ID: 28240572
[TBL] [Abstract][Full Text] [Related]
12. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
Nosova EY; Bukatina AA; Isaeva YD; Makarova MV; Galkina KY; Moroz AM
J Med Microbiol; 2013 Jan; 62(Pt 1):108-113. PubMed ID: 23019190
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic and genotypic characterization of levofloxacin- and moxifloxacin-resistant
Hameed HMA; Tan Y; Islam MM; Guo L; Chhotaray C; Wang S; Liu Z; Gao Y; Tan S; Yew WW; Zhong N; Liu J; Zhang T
J Thorac Dis; 2019 Nov; 11(11):4613-4625. PubMed ID: 31903250
[TBL] [Abstract][Full Text] [Related]
14. Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones.
Firsov AA; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
Antimicrob Agents Chemother; 2005 Jul; 49(7):2642-7. PubMed ID: 15980331
[TBL] [Abstract][Full Text] [Related]
15. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.
Yoshimatsu T; Nuermberger E; Tyagi S; Chaisson R; Bishai W; Grosset J
Antimicrob Agents Chemother; 2002 Jun; 46(6):1875-9. PubMed ID: 12019103
[TBL] [Abstract][Full Text] [Related]
16. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
Shandil RK; Jayaram R; Kaur P; Gaonkar S; Suresh BL; Mahesh BN; Jayashree R; Nandi V; Bharath S; Balasubramanian V
Antimicrob Agents Chemother; 2007 Feb; 51(2):576-82. PubMed ID: 17145798
[TBL] [Abstract][Full Text] [Related]
17. In silico evaluation and exploration of antibiotic tuberculosis treatment regimens.
Pienaar E; Dartois V; Linderman JJ; Kirschner DE
BMC Syst Biol; 2015 Nov; 9():79. PubMed ID: 26578235
[TBL] [Abstract][Full Text] [Related]
18. Optimizing tuberculosis treatment efficacy: Comparing the standard regimen with Moxifloxacin-containing regimens.
Budak M; Cicchese JM; Maiello P; Borish HJ; White AG; Chishti HB; Tomko J; Frye LJ; Fillmore D; Kracinovsky K; Sakal J; Scanga CA; Lin PL; Dartois V; Linderman JJ; Flynn JL; Kirschner DE
PLoS Comput Biol; 2023 Jun; 19(6):e1010823. PubMed ID: 37319311
[TBL] [Abstract][Full Text] [Related]
19. A computational model tracks whole-lung Mycobacterium tuberculosis infection and predicts factors that inhibit dissemination.
Wessler T; Joslyn LR; Borish HJ; Gideon HP; Flynn JL; Kirschner DE; Linderman JJ
PLoS Comput Biol; 2020 May; 16(5):e1007280. PubMed ID: 32433646
[TBL] [Abstract][Full Text] [Related]
20. Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.
Al-Shaer MH; Alghamdi WA; Alsultan A; An G; Ahmed S; Alkabab Y; Banu S; Barbakadze K; Houpt E; Kipiani M; Mikiashvili L; Cegielski JP; Kempker RR; Heysell SK; Peloquin CA
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
